Literature DB >> 16266867

Follicular lymphoma: a therapeutic update.

Antoine Italiano1, Antoine Thyss.   

Abstract

Follicular lymphoma is the most common low-grade non Hodgkin's lymphoma. This indolent disease is usually characterised by an indolent course with a continuous pattern of relapse and a median survival of 10 years. Radiotherapy can be curative in a small proportion of patients with very localized disease, but the majority of patients have advanced disease at diagnosis and it is not clear that any current therapy is curative in this situation. In the last 5 years we have seen a dramatic increase in the number of patients receiving emerging therapies such as antibody therapy combined or not with chemotherapy, radioimmunotherapy or stem cell transplantation. In this article, we will review the available treatments of follicular lymphomas, with special emphasis on published phase III trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16266867

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  4 in total

Review 1.  Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.

Authors:  David H Henry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 2.  Economic burden of follicular non-Hodgkin's lymphoma.

Authors:  Talia Foster; Jeffrey D Miller; Mark E Boye; Mason W Russell
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma.

Authors:  Barbara J Fueger; Kristen Yeom; Johannes Czernin; James W Sayre; Michael E Phelps; Martin S Allen-Auerbach
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

4.  Economic impact of disease progression in follicular non-Hodgkin lymphoma.

Authors:  Roy Beveridge; Sacha Satram-Hoang; Kavita Sail; Joseph Darragh; Clara Chen; Michael Forsyth; Carolina Reyes
Journal:  Leuk Lymphoma       Date:  2011-07-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.